Quarter Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
ending March 2021/Q1 ending March 2021/Q1~2 ending March 2021/Q1~3 ending March 2021/Q1~4 ending March 2022/Q1 ending March 2022/Q1~2 ending March 2022/Year Ended (forecast)
Net sales 29,913 57,817 91,837 121,885 41,157 71,568 135,000
 Pharmaceuticals 26,209 50,296 80,243 106,478 37,050 63,430 119,300
 Functional food 3,703 7,521 11,594 15,406 4,106 8,138 15,700
Operating income 7,522 11,140 20,362 26,134 16,448 21,504 28,000
Ordinary income 7,723 11,248 21,023 26,760 16,598 22,250 28,500
Net income attributable to owners of the parent 5,835 8,073 15,085 20,702 12,341 16,561 21,000
Depreciation and amortization 1,740 3,550 1,453 3,800
Capital investment 999 2,583 1,102 4,800
R&D expenses 2,836 7,659 11,459 16,104 3,699 10,005 26,500
Total assets 178,391 180,453 181,840 197,028 200,114 204,052
Net assets 149,763 152,621 156,256 162,543 170,465 174,890

Net Sales

For 1Q and 2Q of the fiscal year ending March 2022, net sales were 71,568 million yen, an increase of 23.8% from the same quarters of the previous fiscal year. The factors behind the result include sales of Vidaza, a treatment for myelodysplastic syndromes and acute myeloid leukemia (AML), and Uptravi, a treatment for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), and royalty income from overseas sales of these products, as well as income from the sale of priority review vouchers issued by the U.S. Food and Drug Administration (FDA).

Operating income
 

Net income attributable to owners of the parent

Operating income was 21,504 million yen, a 93.0% increase from 1Q and 2Q of the previous fiscal year, and net income attributable to owners of the parent was 16,561 million yen, a 105.1% increase. The factors behind the results include a decrease in the ratio of cost to sales caused by the increase in sales and improvement of the sales mix.

R&D expenses

Cash Flows

Fiscal year
(millions of yen)
ending March 2021/Q1 ending March 2021/Q1~2 ending March 2021/Q1~3 ending March 2021/Q1~4 ending March 2022/Q1 ending March 2022/Q1~2
Cash flow from operating activities 8,127 21,388 13,333
Cash flow from investing activities -2,071 -1,564 -1,954
Cash flow from financing activities -2,899 -6,199 -3,365

Long-term Chronological Data

View long-term chronological data from here.